FDA drug approval delays increase 30% by Q4 2026

Pending drug approvals at the FDA will see a 30% increase in average processing time by Q4 2026 due to leadership vacuum and policy uncertainty. This will disproportionately affect biotech and pharmaceutical stocks with near-term PDUFA dates.

Implied probability (Yes)

78%